Drug intelligence / Profile preview

SKB445

Development stage: Phase 1
Lead developer: Kelun-Biotech
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Intravenous

Overview

SKB445 is a novel antibody-drug conjugate (ADC) developed by Sichuan Kelun Pharmaceutical Research Institute and its subsidiary Kelun-Biotech for the treatment of advanced solid tumors. It utilizes proprietary OptiDC platform technology to optimize the biological characteristics of its target and has demonstrated promising efficacy and safety in preclinical studies. SKB445 is currently in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor activity as monotherapy in patients with advanced solid tumors. The precise molecular target or mechanism of action has not been publicly disclosed as of April 2025.

Targets

MAGEA8 (Melanoma-associated antigen 8)

Beyond the preview

Go deeper on SKB445.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKB445.